TWiV reviews an outbreak of Marburg hemorrhagic fever in Equatorial Guinea, wild poliovirus type 3 shedding from a laboratory in the Netherlands, and white-tailed deer as a reservoir for previous SARS-CoV-2 variants of concern.
In his weekly clinical update Dr. Griffin discusses progress toward poliomyelitis eradication in Afghanistan, reduced risk for Mpox after receipt of 1 or 2 doses of JYNNEOS vaccine compared with risk among unvaccinated persons, reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters, authorized updated (Bivalent) COVID-19 vaccines for children down to 6 months of age, low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster, efficacy of antiviral agents against omicron subvariants BQ.1.1 and XBB, incidence of viral rebound after treatment with Nirmatrelvir-Ritonavir and Molnupiravir, and the effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post–COVID-19 conditions.
In his weekly clinical update Dr. Griffin discusses Mpox (formerly monkeypox) in women: epidemiological features and clinical characteristics of mpox cases in Spain, April to November 2022, triage of patients with Ebola virus disease, SARS-CoV-2 serology and self-reported infection among adults, serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals, sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants, effect of wearing glasses on risk of infection with SARS-CoV-2 in the community, and data-driven identification of post-acute SARS-CoV-2 infection subphenotypes.
In his weekly clinical update Dr. Griffin discusses effectiveness of influenza vaccination of pregnant women for prevention of maternal and early infant Influenza-associated hospitalizations in South Africa, a multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes, single and 2-dose vaccinations with modified vaccinia Ankara-Bavarian Nordic induce durable B cell memory responses comparable to replicating smallpox vaccines, whether the risk of still and preterm birth is affected by the timing of symptomatic SARS-CoV-2 infection during pregnancy, medical masks versus N95 respirators for preventing COVID-19 among health care workers, alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants, real-world evidence of novel treatments for COVID-19 on mortality: a nationwide comparative cohort study of hospitalized patients in the 1st, 2nd, 3rdand 4th wave in the Netherlands, and effectiveness and safety of extended thromboprophylaxis in post-discharge patients with COVID-19.
In his weekly clinical update Dr. Griffin discusses human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks, changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States, updates on COVID-19–related mortality, impact of community masking on COVID-19, effectiveness of the COVID-19 vaccines against hospitalization with Omicron sub-lineages BA.4 and BA.5 in England, cardiovascular outcomes after Tixagevimab and Cilgavimab use for pre-exposure prophylaxis against COVID-19, how Paxlovid is associated with decreased hospitalization rate among adults with COVID-19, inside the mind of an anti-paxxer, and angiotensin receptor blockers for the treatment of COVID-19.
In his weekly clinical update Dr. Griffin discusses the four things to know about RSV, the burden of respiratory syncytial virus in healthy term-born infants in Europe, the diagnostic accuracy of rapid diagnostic tests for Ebola virus disease, evaluating the accuracy of self-collected swabs for the diagnosis of monkeypox, tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations, acute and postacute sequelae associated with SARS-CoV-2 reinfection, clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients, effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy, maternal antibody response and transplacental transfer following SARS-CoV-2 infection or vaccination in pregnancy, impact of community masking on COVID-19, Lifting Universal Masking in Schools – Covid-19 Incidence among Students and Staff, systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients, comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in patients in the community, early adoption of anti–SARS-CoV-2 pharmacotherapies among us veterans with mild to moderate COVID-19, evaluation of viral and symptom rebound differences between Paxlovid and untreated COVID-19 participants, monoclonal antibodies for treatment of SARS-CoV-2 infection during pregnancy, twice daily oral zinc in the treatment of patients with COVID-19, cognitive deficits in long Covid-19, severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration, and long-lasting symptoms after an acute COVID-19 infection and factors associated with their resolution.
In his weekly clinical update Dr. Griffin discusses high demand for Amoxicillin causing shortages amid child RSV surge, epidemiologic and clinical features of children and adolescents aged <18 years with monkeypox, low risk of SARS-Cov-2 transmission by fomites, nucleocapsid antigenemia is a marker of acute SARS-CoV-2 infection, impact of community masking on COVID-19, protection against Omicron from vaccination and previous infection in a prison system, Nirmatrelvir and the risk of post-acute sequelae of COVID-19, Bebtelovimab for high-risk outpatients with early COVID-19 in a large US health system, imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution, can SARS-CoV-2 trigger new onset of autoimmune disease in adults? A case-based review, and retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic.
In his weekly clinical update Dr. Griffin discusses Influenza incidence and vaccine effectiveness during the southern hemisphere influenza season in Chile, Nirsevimab for prevention of RSV infection in healthy late-preterm and term infants, severe Monkeypox in hospitalized patients, reinfections with different SARS-CoV-2 Omicron subvariants, impact of community masking on COVID-19 in Bangladesh, unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses, antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot, immunogenicity of bivalent mRNA vaccine boosters, long-term gastrointestinal sequelae following COVID-19, evaluation of an automated text message–based program to reduce use of acute health care resources after hospital discharge, and how in adults with COVID-19, melatonin was assessed for effects on inflammatory markers, clinical signs and symptoms, and mortality.
In his weekly clinical update Dr. Griffin discusses progress toward poliomyelitis eradication in Pakistan, polio by the numbers , influenza and COVID-19 vaccination coverage among health care personnel, phase 1/2a safety and immunogenicity of an adenovirus 26 vector RSV vaccine encoding prefusion F in adults 18–50 years and RSV seropositive children 12–24 months, receipt of first and second doses of JYNNEOS vaccine for prevention of Monkeypox, distinguishing SARS-CoV-2 persistence and reinfection, Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages, association between regular physical activity and the protective effect of vaccination against SARS-CoV-2 in a South African case, COVID-19 outcomes in solid organ transplant recipients who received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab treatment, Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralizing antibodies, and Tocilizumab versus Baricitinib in hospitalized patients with severe COVID-19.
In his weekly clinical update Dr. Griffin discusses the prediction of upcoming global infection burden of influenza seasons after relaxation of public health and social measures during the COVID-19 pandemic, severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters, and how successful immunomodulators for treatment of COVID-19 have opened the pathway for comparative trials.